Ubiquinol (Reduced COQ10) for Patients With Sepsis

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

October 31, 2012

Primary Completion Date

April 30, 2014

Study Completion Date

April 30, 2014

Conditions
Sepsis
Interventions
DRUG

Ubiquinol

Depending on the patient's ability to swallow pills, patients in the experimental group will receive 200mg Ubiquinol in either a pill or a liquid. The liquid form of the study med will be mixed with 50 milliliters of Ensure (a dietary supplement) to ensure blinding. This will be given every 12 hours for 7 days or until hospital discharge.

DIETARY_SUPPLEMENT

Placebo

Depending on the patient's ability to swallow pills, patients in the control group will receive a placebo pill or a liquid placebo, which is 50 milliliters of Ensure (a dietary supplement). This will be given every 12 hours for 7 days or until hospital discharge.

Trial Locations (1)

02115

Beth Israel Deaconess Medical Center, Boston

All Listed Sponsors
collaborator

Kaneka Medical America LLC

INDUSTRY

lead

Beth Israel Deaconess Medical Center

OTHER

NCT01948063 - Ubiquinol (Reduced COQ10) for Patients With Sepsis | Biotech Hunter | Biotech Hunter